Novel Protease Inhibitors for the Treatment of Neurological Disorders

NeurAegis, Inc. is a late preclinical stage neuropharmaceutical company pioneering the development of breakthrough treatments for neurological disorders including traumatic brain injury (TBI)/concussion and epilepsy. Our initial focus is developing first-in-class, novel protease inhibitors for TBI where there are currently no FDA approved treatments.

TBI/Concussion

NeurAegis’s first indication is traumatic brain injury (TBI)/concussion. Traumatic Brain Injury (TBI) is a significant public health problem in the United States.  In the US, over 3.8 million sports- and recreation-related concussions are reported per year (www.brainline.org), and, according to the CDC, it is likely that many more TBI cases are never reported. In recent years, repeated mild traumatic brain injury has received a lot of attention, after it was found that many military veterans and athletes subjected to repeated concussions exhibit a chronic degenerative disease referred to as Chronic Traumatic Encephalopathy (CTE).

​

Traumatic brain injury (TBI) is a major cause of death and disability in the United States. Consequences of TBI can last a few days or for the remaining of the lives of the persons who survive, and it can affect cognitive, emotional and motor functions.  There is urgent unmet medical need for treatments for TBI and concussions. Currently there are no treatments targeting the major feature of TBI, which is neuronal damage and neuronal death that take place in the hours/days following the injury.

Highlights

• Novel, first in class compounds (protease inhibitors) for treating multiple neurological disorders with significant unmet need

• Lead indication is concussion, where there is currently no FDA approved medication

• Awarded $3.8M DOD grant for concussion therapy

• Large addressable markets

  • >3.8 million sports- and recreation-related concussions per year in the US  (Source: www.brainline.org)​

  • Epilepsy drug market to reach >$5B by 2024 (Source: Grand View Research)

• Strong intellectual property​

• Experienced, proven leadership team